Literature DB >> 11401967

Impact of genotypic variation of Borrelia burgdorferi sensu stricto on kinetics of dissemination and severity of disease in C3H/HeJ mice.

G Wang1, C Ojaimi, R Iyer, V Saksenberg, S A McClain, G P Wormser, I Schwartz.   

Abstract

Various genotypes of Borrelia burgdorferi sensu stricto have been previously identified among a large collection of isolates cultured from patients with Lyme disease in the United States. Furthermore, association of specific genotypes with hematogenous dissemination early in the disease course has been observed. The present study assessed kinetics of spirochete dissemination and disease severity in C3H/HeJ mice infected with two different genotypes of B. burgdorferi. Spirochete load in plasma and ear and other tissue samples of infected mice was measured by quantitative PCR, and these data were compared to those obtained by culture and histopathologic analysis. In mice infected with isolate BL206 (a type 1 strain), the peak number of spirochetes was observed in plasma between day 4 and 7, in heart and ear tissue on day 14, and in joints on day 28 postinoculation. There was a correlation between the peak number of spirochetes in plasma on day 4 or 7 and that in ear biopsy and joint specimens on day 14. By contrast, spirochete burdens in plasma of mice infected with isolate B356 (a type 3 strain) were 16- and 5-fold lower than those of BL206-infected mice on days 7 and 14 of infection, respectively. Similarly, approximately 6- and 13-fold fewer spirochetes were detected in the heart tissues of B356-infected mice compared to BL206-infected mice. Histopathologically, severe arthritis and aortitis were noted only in mice infected with isolate BL206. Spirochete dissemination and disease severity vary significantly in mice infected with distinct genotypes of B. burgdorferi, suggesting that genotypic differences in the infecting spirochetes play a key role in the pathogenesis and development of clinical disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11401967      PMCID: PMC98500          DOI: 10.1128/IAI.69.7.4303-4312.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

Review 1.  European Union Concerted Action on Risk Assessment in Lyme Borreliosis: clinical case definitions for Lyme borreliosis.

Authors:  G Stanek; S O'Connell; M Cimmino; E Aberer; W Kristoferitsch; M Granström; E Guy; J Gray
Journal:  Wien Klin Wochenschr       Date:  1996-12-13       Impact factor: 1.704

2.  Molecular typing of Borrelia burgdorferi from Lyme disease patients by PCR-restriction fragment length polymorphism analysis.

Authors:  D Liveris; G P Wormser; J Nowakowski; R Nadelman; S Bittker; D Cooper; S Varde; F H Moy; G Forseter; C S Pavia; I Schwartz
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

Review 3.  Immunological and molecular variability of OspA and OspC. Implications for Borrelia vaccine development.

Authors:  B Wilske; U Busch; V Fingerle; S Jauris-Heipke; V Preac Mursic; D Rössler; G Will
Journal:  Infection       Date:  1996 Mar-Apr       Impact factor: 3.553

4.  Arthritis severity and spirochete burden are determined by serotype in the Borrelia turicatae-mouse model of Lyme disease.

Authors:  P M Pennington; C D Allred; C S West; R Alvarez; A G Barbour
Journal:  Infect Immun       Date:  1997-01       Impact factor: 3.441

5.  Complement-mediated serum sensitivity among spirochetes that cause Lyme disease.

Authors:  A P van Dam; A Oei; R Jaspars; C Fijen; B Wilske; L Spanjaard; J Dankert
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

6.  Variation in antigenicity and infectivity of derivatives of Borrelia burgdorferi, strain B31, maintained in the natural, zoonotic cycle compared with maintenance in culture.

Authors:  W T Golde; M C Dolan
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

7.  Genetic diversity of Borrelia burgdorferi in lyme disease patients as determined by culture versus direct PCR with clinical specimens.

Authors:  D Liveris; S Varde; R Iyer; S Koenig; S Bittker; D Cooper; D McKenna; J Nowakowski; R B Nadelman; G P Wormser; I Schwartz
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

8.  Molecular typing of Borrelia burgdorferi sensu lato by PCR-restriction fragment length polymorphism analysis.

Authors:  D Liveris; A Gazumyan; I Schwartz
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

9.  Association between different clinical manifestations of Lyme disease and different species of Borrelia burgdorferi sensu lato.

Authors:  T Balmelli; J C Piffaretti
Journal:  Res Microbiol       Date:  1995-05       Impact factor: 3.992

10.  Identification of novel insertion elements, restriction fragment length polymorphism patterns, and discontinuous 23S rRNA in Lyme disease spirochetes: phylogenetic analyses of rRNA genes and their intergenic spacers in Borrelia japonica sp. nov. and genomic group 21038 (Borrelia andersonii sp. nov.) isolates.

Authors:  R T Marconi; D Liveris; I Schwartz
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

View more
  80 in total

1.  Geographic variation in the relationship between human Lyme disease incidence and density of infected host-seeking Ixodes scapularis nymphs in the Eastern United States.

Authors:  Kim M Pepin; Rebecca J Eisen; Paul S Mead; Joseph Piesman; Durland Fish; Anne G Hoen; Alan G Barbour; Sarah Hamer; Maria A Diuk-Wasser
Journal:  Am J Trop Med Hyg       Date:  2012-06       Impact factor: 2.345

2.  Failure of topical antibiotics to prevent disseminated Borrelia burgdorferi infection following a tick bite in C3H/HeJ mice.

Authors:  Gary P Wormser; Thomas J Daniels; Susan Bittker; Denise Cooper; Guiqing Wang; Charles S Pavia
Journal:  J Infect Dis       Date:  2011-09-19       Impact factor: 5.226

Review 3.  [Diagnostic vitrectomy in uveitis: possibilities of molecular biology].

Authors:  M D Becker; B Bodaghi; F G Holz; N Harsch; P Le Hoang
Journal:  Ophthalmologe       Date:  2003-10       Impact factor: 1.059

4.  Culture of the entire mouse to determine whether cultivable Borrelia burgdorferi persists in infected mice treated with a five-day course of Ceftriaxone.

Authors:  Charles S Pavia; Gary P Wormser
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 5.  Lyme arthritis: current concepts and a change in paradigm.

Authors:  Dean T Nardelli; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

6.  Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.

Authors:  Charles Pavia; Mario A Inchiosa; Gary P Wormser
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

7.  Analysis of Borrelia burgdorferi genotypes in patients with Lyme arthritis: High frequency of ribosomal RNA intergenic spacer type 1 strains in antibiotic-refractory arthritis.

Authors:  Kathryn L Jones; Gail A McHugh; Lisa J Glickstein; Allen C Steere
Journal:  Arthritis Rheum       Date:  2009-07

8.  Distribution of the Lyme disease spirochete Borrelia burgdorferi in naturally and experimentally infected western gray squirrels (Sciurus griseus).

Authors:  Sarah Leonhard; Kelly Jensen; Daniel J Salkeld; Robert S Lane
Journal:  Vector Borne Zoonotic Dis       Date:  2010-06       Impact factor: 2.133

9.  Maternal Antibodies Provide Bank Voles with Strain-Specific Protection against Infection by the Lyme Disease Pathogen.

Authors:  Andrea Gomez-Chamorro; Vanina Heinrich; Anouk Sarr; Owen Roethlisberger; Dolores Genné; Cindy Bregnard; Maxime Jacquet; Maarten J Voordouw
Journal:  Appl Environ Microbiol       Date:  2019-11-14       Impact factor: 4.792

10.  Comparison of disseminated and nondisseminated strains of Borrelia burgdorferi sensu stricto in mice naturally infected by tick bite.

Authors:  Marc C Dolan; Joseph Piesman; Bradley S Schneider; Martin Schriefer; Kevin Brandt; Nordin S Zeidner
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.